BeiGene Ltd. (BGNE)
NASDAQ: BGNE
· Real-Time Price · USD
184.71
0.90 (0.49%)
At close: Dec 31, 2024, 9:00 PM
0.49% (1D)
| Bid | 180.03 |
| Market Cap | 20.21B |
| Revenue (ttm) | 3.32B |
| Net Income (ttm) | -3.15B |
| EPS (ttm) | -8.19 |
| PE Ratio (ttm) | -22.553113553113555 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 189.93 |
| Volume | 329,397 |
| Avg. Volume (20D) | 357,765 |
| Open | 184.00 |
| Previous Close | 183.81 |
| Day's Range | 183.91 - 187.42 |
| 52-Week Range | 126.97 - 248.16 |
| Beta | 0.63 |
About BGNE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BGNE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
BeiGene Ltd. is scheduled to release its earnings on Feb 24, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+7.31%
BioGene shares are trading higher after the compan...
Unlock content with
Pro Subscription
6 months ago
-5.56%
BeiGene shares are trading lower. The company reported Q3 financial results.
1 month ago · businesswire.com
BeiGene to Announce First Quarter 2025 Financial Results on May 7SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will re...
3 months ago · seekingalpha.com
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with ...
